TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Moderate to Severe Facial Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 12 and 45 years of age.~* Has a diagnosis of moderate to severe facial acne vulgaris with no more than two nodules on the face~Exclusion Criteria:~* Is allergic to tetracycline-class antibiotics or to any ingredient in the study medication.~* Has a history of pseudomembranous colitis or antibiotic-associated colitis.~* Has a history of hepatitis or liver damage or renal impairment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Doxycyline 0.6 mg/kg/day (Type: EXPERIMENTAL): Doxycycline dosed at 40 mg/day to subjects of appropriate weights
- Doxycycline 1.2 mg/kg/day (Type: EXPERIMENTAL): Doxycycline dosed at 80 mg/day to subjects of appropriate weights
- Doxycycline 2.4 mg/kg/day (Type: EXPERIMENTAL): Doxycycline dosed at 160 mg/day to subjects of appropriate weights
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Mobilization in Hospitalized Patients With Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years old~* need for intermittent hemodialysis during hospitalization~* hypoalbuminemia (albumin\<3g/dl)~Exclusion Criteria:~* allergy to the components of albumin

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albumin (Type: ACTIVE_COMPARATOR): albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
- normal saline (Type: PLACEBO_COMPARATOR): 0.9% sodium chloride (normal saline (NS)) given intravenously at the start of IHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Fever Due to Malaria With Ibuprofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Uncomplicated falciparum malaria~* Asexual parasitaemia between 20,000 and 200,000/µL~* Fever with temperature above 38 °C or history of fever during the preceding 24 hours~* Informed consent~Exclusion Criteria:~* Effective anti-malarial treatment for the present attack~* Antipyretic use within 6 hours of presentation~* Contraindications to the use of ibuprofen (history of asthma, dyspeptic symptoms, gastro-intestinal bleeding, or allergy to ibuprofen)~* Mixed plasmodial infection~* Haemoglobin \< 7 g/dL~* Packed-cell volume \< 20%~* White cell count \> 16,000/L~* Platelet count \< 40,000/µL~* Schizontaemia \> 50/µL~* Impaired consciousness~* Convulsions or history of convulsions~* Concomitant diseases masking assessment of response

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes mellitus (T2DM) controlled with diet and exercise alone or are stable on a single oral antihyperglycemic medication (OAM), metformin, acarbose, or sulphonylureas only (other types of OAM \[dipeptidyl peptidase IV inhibitors, sodium-glucose cotransporter-2 inhibitors, and thiazolidinediones\] are not allowed in this study), for at least 3 months~* Have a body mass greater than or equal to (≥)23 kilograms per square meter (kg/m²), inclusive~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to Visit 1~* Have a history of heart block or PR interval greater than (\>)220 milliseconds (msec) or any abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have a history or presence of pancreatitis or gastrointestinal (GI) disorder or a GI disease that impacts gastric emptying or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors~* Have known allergies to tirzepatide, GLP-1 analogs, or related compounds or any components of the formulation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo once weekly (QW) subcutaneously (SC).
- Tirzepatide - Cohort 1 (2.5 to 10 Milligram (mg)) and Cohort 2 (2.5 to 15 mg) (Type: EXPERIMENTAL): Participants in Cohort 1 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15.~Participants in Cohort 2 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15, 12.5 mg for Weeks 16 through 19, and 15 mg for Weeks 20 through 23.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zonisamide for Weight Reduction in Obese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: Age 18-65 years; BMI 30-50~Exclusion Criteria:~Secondary obesity; Significant cardiovascular disease; Stroke, seizure disorder or other significant neurological disease; Significant liver or gallbladder disease; Significant renal disease or history of kidney stones; HIV positive status; Diabetes mellitus; Untreated or unstable hypothyroidism Malignancy in the past 5 years; Concomitant medications that cause significant weight gain or weight loss; Concomitant use of prescription or OTC weight loss medications; Had bariatric surgery or planning surgery in the next 1 year; Weight change of more than 4 kg in the past 3 months; Suicidal subjects; Major depression in the past 6 months; History of psychosis, bipolar disorder, or severe personality disorders; Subjects taking antipsychotics or mood stabilisers; Alcohol or substance abuse in the past 6 months; Currently taking zonisamide or other antiepileptic drugs; History of hypersensitivity to zonisamide or sulfonamides; Pregnant or planning pregnancy in the next year, or breastfeeding; Severe physical disability; Current participation in a commercial weight loss program or planning to participate; Currently following low-carbohydrate, high protein, high fat diet; Use of investigational medications or devices (current or past 4 weeks)~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Zonisamide 400 mg
- B (Type: EXPERIMENTAL): Zonisamide 200 mg
- C (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man ≥ 18 years~* Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.~* Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free technique) to be performed according to standard surgical technique under general anesthesia.~Exclusion Criteria:~* Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.~* Scheduled for bilateral inguinal herniorrhaphy.~* Undergone a prior herniorrhaphy on the side scheduled for repair.~* Undergone major surgery within 3 mos of the scheduled herniorrhaphy.~* Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.~* Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).~* Used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2, 5x5cm bupivacaine collagen sponges (Type: EXPERIMENTAL): collagen sponges
- 2, Placebo collagen sponges (Type: PLACEBO_COMPARATOR): Placebo collagen sponges

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients with a diagnosis of systemic lupus erythematosus (SLE) according to the criteria of American Rheumatic Association, 1982, aged between 12-50 years, with score of SLE-DAI (Disease Active Index) of more than 12 (not including class V LN).~2. Patients diagnosed according to ISN/RPS 2003 classification criteria: class Ⅲ, Ⅳ, Ⅳ + Ⅴ, Ⅲ + Ⅴ LN by renal biopsy within 3 months, CI\< 4，Scr\< 3 mg/dl.~3. Patients with a proteinuria ≥ 1.5 g/24h, or active urine sediment.~4. Patients who signed written informed consent forms (patients less than 18 years old with their parents/legal representative' signatures), and have given their consent to follow all study procedures and follow-ups.~Exclusion Criteria:~1. Patients who have received treatment of cytotoxic drugs such as cyclophosphamide (CTX), cyclosporine A for more than 1 week within three months.~2. Patients with serum creatinine ≥ 3 mg/dl（265 μmol/L).~3. Patients with severe infection or central nervous system symptoms.~4. Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit or who have active hepatitis.~5. Patients who have abnormal blood glucose, with a fasting blood glucose \> 6.2 mmol/L or post meal blood glucose \> 11.2 mmol/L.~6. Patients who are pregnant or lactating.~7. Patients who are known to be allergic to a macrolide.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- FK506+MMF (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: t-RNS After Hand Recovery in Chronic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Episode (1 or more than one) of stroke at least 6 months prior~* Able to follow 3-step commands to rule out severe aphasia~* Unilateral hemiparesis~* Able to speak english~* No active drug or alcohol abuse, schizophrenia, other neurological or medical conditions that would confound results, or refractory depression~* Able to actively flex and extend the more-affected shoulder and elbow at least 30°.~* Able to elicit motor evoked potential in the flexor carpii radialis and extensor carpii radialis muscles of the affected hand.~Exclusion Criteria:~* Spasticity greater than equal to 2 on the Modified Ashworth Scale in shoulder, elbow, wrist and finger joints of the more-affected upper extremity~* Scores \> 3 on the Amount scale of Motor Activity Log indicating good use of the more-affected hand~* Has ataxia determined via finger-to-nose testing section of the Fugl Meyer Upper Extremity assessment~* Has proprioceptive sensory deficits determined via a score of 2 on the position sense section (section H) of the Fugl Meyer Upper Extremity assessment proprioception~* Excessive pain \> equal to 4 on Visual Analog Scale in the more-affected upper extremity~* Skin lesions on the more-affected upper extremity and scalp~* Individuals with implanted devices that may be affected by electrical stimulation~* Participating in concurrent therapy~* Individuals with seizures~* History of seizures, schizophrenia, Bipolar disorder (type I or II) \[Answer yes to questions 16 and items of the (hypo) maniac module of MINI\], current moderate, severe depression (Scores of \>10 on PHQ-9) and other neurological or medical conditions that could confound results.~* Individuals with refractory depression, which are defined as individuals with severe depressive disorder that are resistant to antidepressants (Scores of \>10 on PHQ-9).~* Current treatment with antipsychotics or benzodiazepines.~* Current treatment with bupropion, which may induce seizure.~* Scores \< 24 on Mini Mental Status Examination~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- tRNS and FES facilitated task practice (Type: ACTIVE_COMPARATOR): In this arm, participants received real transcranial random noise stimulation with FES facilitated task practice
- sham tRNS and FES facilitated task practice (Type: SHAM_COMPARATOR): In this arm, participants received sham transcranial random noise stimulation with FES facilitated task practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of nonpsychotic major depressive disorder at least 4 weeks prior to study entry~* Clinical Global Impression severity score of 4 or greater~* Children's Depression Rating Scale score of 40 or greater~* Currently attending school~* Willing and able to use acceptable methods of contraception, if applicable~* In good general health~* Parent or guardian willing to provide informed consent, if applicable~Exclusion Criteria:~* History of psychotic disorders~* Alcohol or substance abuse or dependence within 6 months prior to study entry~* History of anorexia nervosa or bulimia~* Chronic medical illness requiring regular medication~* Current use of medication with psychotropic effects~* First-degree relatives (e.g., mother, father, sister, brother) with bipolar I disorder~* At risk for suicide~* Failure of a previous adequate treatment with fluoxetine (defined as at least 40 mg/day for 4 weeks)~* IQ less than 80~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
- 2 (Type: ACTIVE_COMPARATOR): Continuation phase drug therapy only for 6 more months following acute treatment response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 6 months - 10 years, without severe malnutrition and with a slide-confirmed mono-infection of P. falciparum, and asexual parasitemia between 250 - 200000 asexual parasites/µl will be included.~* Other inclusion criteria will include, absence of dangers signs (see Exclusion Criteria), axillary temperature \> 37.5oC or a history of fever within the past 24 hours and ability to swallow oral medications.~* The ability and willingness to attend scheduled follow-up visits and an informed consent provided by parent or guardian will also be considered as important inclusion criteria without which a patient will not be enrolled into the study.~* Patients shall not be excluded on the basis of reported prior treatment with other anti-malarial drugs other than DHA-PQ within the past 24 hours if they have fever (axillary temperature \> 37.50C) and parasitemia.~* Patients should have stable residence within the catchment area throughout the study period~Exclusion Criteria:~* The exclusion criteria will include: presence of general danger signs or signs of severe falciparum malaria according to the definitions of WHO (Appendix 6), severe anaemia (Hb \< 5 g/dL) and mixed or mono-infection with species other the P. falciparum.~* Others will include severe malnutrition (defined as a child whose growth standard is below -3 z-score or symmetrical oedema involving at least one of the feet or a mid-upper arm circumference \< 110 mm.~* Patients with febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases and HIV/AIDS) will be excluded.~* Furthermore, patients under regular medication, which may interfere with anti-malarial pharmacokinetics and those with a history of hypersensitivity reactions or contraindications to the artemisinin-based therapy, piperaquine or the alternative treatment, will not be included into the study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine
- B (Type: EXPERIMENTAL): Dihydroartemisinin-piperaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of the My HealtheVet for Health Information Sharing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Upcoming Non-VA provider appointment~* Take 5 or more prescribed medications~* Have or obtain a My HealtheVet premium account~* Access to computer, printer, \& Internet to complete study protocol~Exclusion Criteria:~* No non-VA provider or upcoming appointment~* Less than 5 medications~* No premium MHV account

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- My HealtheVet Training (Type: EXPERIMENTAL): Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
- Internet Skills Training (Type: ACTIVE_COMPARATOR): Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of L-NAME and Midodrine to Increase MAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Spinal Cord Injured Subjects:~* chronic spinal cord injury (1 year post injury) with a seated MAP of 65mmHg (almost all individuals with tetraplegia demonstrate this)~* Male or female with an age of 18 - 65 years~Control Subjects:~* Male or female with an age of 18 - 65 years~Exclusion Criteria:~Spinal Cord Injured Subjects:~* acute illness~* cardiovascular disease~* renal disease~* medications that affect the cardiovascular system~Control Subjects:~* acute illness~* cardiovascular disease~* renal disease~* medications that affect the cardiovascular system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Midodrine (Type: EXPERIMENTAL): A drug to treat low blood pressure.
- L-Name (Type: EXPERIMENTAL): L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: A pill with an inactive substance that looks like the study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete